By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Qiagen's acquisition strategy remains unchanged, and the firm is more likely to make smaller deals than any sort of big, transformative transaction, a company spokesperson told GenomeWeb Daily News today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.